Journal
EXPERT OPINION ON EMERGING DRUGS
Volume 13, Issue 1, Pages 145-158Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728214.13.1.145
Keywords
anti-oxidants; drugs; non-alcoholic fatty liver
Categories
Ask authors/readers for more resources
Background: Non-alcoholic fatty liver disease (NAFLD) is a condition of emerging relevance that includes different forms of chronic liver damage, from a simple fatty infiltration (steatosis) of hepatocytes to steatohepatitis (NASH) with fibrosis. This last form may evolve to cirrhosis and hepatocellular carcinoma. Objective: To discuss therapeutic management of NAFLD. Theoretically, only patients with non-alcoholic steatohepatitis (NASH) need to be treated, as only NASH may evolve to cirrhosis. Differentiation between steatosis and NASH currently requires a liver biopsy. Methods: We discuss different therapeutic approaches proposed in literature for patients with NAFLD. Results: The treatment of associated conditions leads to an improvement of NAFLD and NASH. No specific drug is actually present to treat liver steatosis or NASH. Conclusions: The treatment of NAFLD depends on the individual characteristics of each patient. Diet and physical exercise may be considered a basal universal approach. Future research will discover possible specific liver drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available